Mail

Biology:Big or little? Big science, with very few exceptions (one being the Human Genome Project), is a waste of money.1 Big science is grossly inefficient, and is designed to impress non-scientists (including university administrators). Anyone who has experienced the difference between forced collaborations (big science) and real collaborations (spontaneous, as-needed interactions) knows this is tru

Written byThe Scientist
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Big science, with very few exceptions (one being the Human Genome Project), is a waste of money.1 Big science is grossly inefficient, and is designed to impress non-scientists (including university administrators). Anyone who has experienced the difference between forced collaborations (big science) and real collaborations (spontaneous, as-needed interactions) knows this is true.

Basic research does lead to cures for diseases as well as other improvements in quality of life. Big science enriches a few empire builders but produces nothing.

Contrary to Steven Wiley's claim, Congress does not respond to the voters. The voters have said for decades they want more money spent on medical research. Congress responds to lobbyists and they respond to money. We need better lobbyists.

Biomedical research in the United States is now in a state of crisis from which it may not recover. Diverting money from real science into flashy projects may fool a few politicians ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies